Editorial: The FDA and ophthalmic therapeutics.
D003365:Costs and Cost Analysis; D004341:Drug Evaluation / Q000379:methods*; D006801:Humans; D007634:Keratitis / Q000188:drug therapy; D007635:Keratitis, Dendritic / Q000188:drug therapy; D009181:Mycoses / Q000188:drug therapy; D010866:Natamycin / Q000627:therapeutic use; D009885:Ophthalmology; D014271:Trifluridine / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D010866:Natamycin; D014271:Trifluridine